Annual Meeting Presentation

TruScreen
A World Without
Cervical Cancer
AGM September 2024
Auckland, New Zealand
Marty Dillon, CEO

2
⚫Who is TruScreen
⚫Key achievements in financial year 2024
⚫Outlook and goals for FY 2025
⚫Market Expansion
⚫Technology Improvement, COGS and Cost Reduction
⚫Q&A
⚫Appendix: TruScreen Technology
TruScreen
A Growth Company

Who is
TruScreen
3

Who is TruScreen
4
TruScreen Group Ltd is
listed on both the
Australian (ASX) and New
Zealand (NZX) stock
exchanges, with a common
ticker code of TRU.
Shares on Issue:
552,591,116
TruScreen Group Ltd is a
revenue generating Life
Science company with
annual sales
exceeding NZD $2m.
Market Capitalisation at
28 August 2024:
NZD $9,946,640

The TruScreen Real Time
Cervical Cancer Screening
DEVICE
5
Recurring Revenue Model
The TruScreen DISPOSABLE Single
Use Sensor (SUS) – a consumable
product delivering recurring
revenue.
For each patient screened with the TruScreen device a new
disposable Single Use Sensor must be used.
TruScreen manufactures two devices - one made in China for
use in China, where locally products have preferential market
access, and one made in Australia for other markets

Distribution Network
Local knowledge and influence
End-user management
•Lean headquarters
•Recurring revenue stream
from consumable SUS
•Intellectual Property
•Service & Manufacturing
End Users
•Public and private hospitals
•Public and Private Health Clinics
•Public health initiatives
•Governments& Non-Government
Organisations
6
Effective co-invest model
with global distribution

7
TruScreen
World Class technology made simple
Real-time, AI-enabled, primary cervical
cancer screening device for detection of pre-
cancerous and cancerous cervical tissue
Handheld device
⚫Optical and electrical measurements painlessly detect
abnormalities in cervical tissue
⚫A Single Use Sensor (SUS) used for each exam,
preventing cross-contamination
⚫AI-enabled algorithm provides Normal/Abnormal
result immediately
⚫No cervical cell or tissue collection
⚫EU certified (CE Mark) and ISO 13485 compliant class
IIa medical device
Intelligent Cradle
Single Use
Sensor (SUS)

Key Achievements
8

9
FY2024 Financial Results
⚫Sales increased 27% YOY
⚫SUS Sales increased 25% YOY
⚫Revenue increased 18% YOY
⚫EBITDA improved 15% YOY
⚫Net Assets increased 28% YOY
⚫Cash increased 23% YOY
⚫China SUS/Device Pull Through increased 40% YOY
KEY FINANCIALS
NZD (m)
FY 22
Actual
FY 23
Actual
FY 24
Actual
Sales1.71.662.1
Total Revenue2.72.22.6
COGS1.31.31.4
R&D1.50.90.9
EBITDA-2.7-2.4-2.0
Write off of Non-Current
Assets
-4.6-0.05-
Amortisation &
Depreciation
-0.6--
LOSS FOR YEAR-7.9-2.4-2.0
Net Assets3.42.53.2
Cash2.82.22.7

Key Achievements
FY2024/25
10
In March 2024 TruScreen Group Limited
closed a NZD $2.6m rights issue and
placement confirming the markets confidence
in our growth strategy.
Non Executive Chairman, Tony Ho
“this is an outstanding result and demonstrated the
confidence that investors have in the company”

Outlook strategy
and goals FY2025
11

12
Outlook Strategy and goals
It is the key aim of TruScreen Group Ltd to be month to month cash flow positive by 31 March 2025
Lowering COGS
Market Growth
Lowering
operating costs

The Global
Market
13

14
Source: Human papillomavirus and cancer (who.int)
The Global Market
Cervical cancer is the
fourth most common
cancer in women globally
Globally, 604000 new
cases and 342 000
deaths were
recorded in 2020
About 90% of these
deaths occurred in low-
and middle-income
countries
The highest rates are
inAfrica, Central
America and South-
East Asia.

15
TruScreen’s presence and markets*
European Union:
CE Mark ISO 13485
Registered with:
•TGA, Australia
•MHRA, UK
•NMPA, China
•SFDA, Saudi Arabia
•Roszdravnadzor, Russia
•COFEPRIS, Mexico
•WAND New Zealand
China
477M
RUSSIA
48M
&
CENTRAL
ASIA
13M
INDONESIA
96M
MEXICO
46M
VIETNAM
36M
SAUDI
11M
POLAND
13M
SOUTHERN
& CENTRAL
AFRICA
134M
INDIA
468M
UZBEKISTAN
12M
Current Markets
Targeting commercial rollout
Markets under review
* Number of eligible women to of screening age: CIA World Fact Book Women 15-64,

Market
Expansion
16

17
Market Expansion
TruScreen sales grow 27% YOY, exceeding China and APAC CAGR forecasts for HPV screening (10%).
Business Market Insights
June 2023:
The Asia Pacific CIN & HR-HPV
treatment market is expected to
grow from US$ 2,738.94 million
in 2023 to US$ 3,949.99 million
by 2028.
It is estimated to grow at a CAGR
of 7.6% from 2023 to 2028.
1
2
HPV Test Market Revenue (Million USD) and Growth Rate (2018-2028)

18
Device installations and SUS pull through
Where we are

MAXIMISE
19
19
Market Expansion
MAXIMISE
Seize the COGA Blue
Book & CSCCP national
guideline inclusion and
focus on Key Provinces
to grow sales in China
EXPAND
Expand markets in,
Mexico, Vietnam,
Zimbabwe and East
Africa, Middle East and
Indonesia
GROW
Grow commercial
presence in South East,
South and Central Asia,
Central and Eastern
Europe
123

China
20

21
China
TruScreen’s largest market
and No 1 Focus for Sales
Over 477 million women
of screening age, with
158 million women
needing to be screened
each year*
High government
support for cervical
cancer screening
Made in China
status from 2021 –
preferred market
access in China –
NMPA approval
* CIA World Fact Book May 2024 Women aged 15-64 yrs

22
Source: http://www.xinhuanet.com/english/2020-
12/11/c_139580487.htm
Market Expansion China
TruScreen listed in COGA
(China Obstetrics and
Gynaecology Association)
Blue Book
TruScreen Listed in
CSCCP (China Society
for Colposcopy and
Cervical Pathology)
Guideline
Installation in key opinion
leading hospital in
Jiangsu province
(population 85 m) -
Affiliated Hospital of
Nantong University
(potential for 1000 SUS per
month)
This listing was
re-inforced by
sponsorship of the
CSCCP annual conference
in Tianjin in May 2024.

23
TruScreen’s largest market and growth opportunity
Growing recurring revenue
per device - from 85 to
> 129 consumable
sales (Single Use
Sensors) per device per
month over the past 12
months
Consumable (Single
Use Sensor) sales for
FY24 were a 24%
increase on FY23
Top 6 key hospitals
using more than 500
Single Use Sensors
per device per month
Estimated potential for
this to grow to 290
Single Use Sensors
per device per month
Price review completed
with a price increase
for our consumable
Single Use Sensor

24
China potential for SUS pull through growth
The devices in China:
Currently have an average pull
through of 129 SUS per device
per month.
The potential average pull
through of SUS exceeds 290 per
month.
Key accounts reach 500+ SUS
pull through.
1
2
3

25
TruScreen FY2025 Growth Pipeline
Target > 150 devices in full commercial use by March 31 2025
Device Installation Pipeline
•97 hospitals have installed
TruScreen and actively use our
device for cervical cancer
screening
•25 hospitals have received
TruScreen approval, awaiting
tender completion
•10 tenders won and awaiting
hospital installation
97
hospitals
25
hospitals
10
tenders
Target >150 devices

26
Source: https://childrensheartlink.org/new-funding-from-
conocophillips-china/
Increase Provincial Pricing Approvals from 11 to 16
Increase commercial user installation base from 97 to 150
Focus on Key Expansion Provinces
Jiangsu, Zhejiang and Guangzhou
Increase SUS pull through (SUS per device per month)
from 129 to 290
Accelerate Adoption in National Health Check program
(targeting 10,000 women in 10 hospitals over 3 years)
China Key Objectives

Vietnam
27

28
Market opportunity
This reduces the hospital purchasing approval time from 18
months to 2 – 4 weeks
36 million women of
screening age*
No centralised
screening programs
Booming economy
and middle class
Ministry Of Health (MOH)
has listed TruScreen on
the National Technical
List of approved
technologies

29
Source: https://www.vietnam-briefing.com/news/why-investors-
should-be-optistimic-vietnams-healthcare-industry.html/
Focus on Public Hospitals
Target list of 64 Hospitals identified with installations to
roll out across FY 25 and FY26
Rollout commenced with the first 10 Devices and 1800
Single Use Sensors purchased
Aim is 25 devices installed by March 31, 2025
Vietnam Key Objectives

Mexico
30

31
Market opportunity
46 million women of
screening age
COFEPRIS approval
granting access to public
health sector, where over
70% of women receive
medical care
If approved this
program will have a
potential for 20
devices, and 10,000
SUS per month
TruScreen using this
approval to focus on a
tender for Mexico City
(Greater Mexico City has a
population of 22m and a
GDP of USD $411 Billion).
Private sector sales to be
rationalised, with a
focus on higher use
clinics located to
closer to Mexico City
New Government with
female President

32
Eastern Europe
and Central Asia

33
Poland
13 million women of
screening age
TruScreen won the top award in
the Mother and Child Institute
challenge for healthcare
companies. This is the
largest public hospital
network for womens health
in Poland.
As a result of this GE Health
introduced TruScreen to a
major private clinic group
where we are being validated
for replacement of Liquid
Based Cytology for all their
private patients.

34
Uzbekistan
12 million women of
screening age
TruScreen is in discussions with
the Uzbekistan Ministry of
Health and representatives
from the office of the
President for use as a
screening solution in regional
centres and remote
communities.
TruScreen’s Russian distributor
is expanding activities to
include Kazakhstan,
Kyrgyzstan, Belarus and
Armenia and they have
purchased 4 devices to satisfy
initial orders in this expanded
market.
Russia and Central Asia
61 million women of
screening age

35
Africa and
Middle East

36
Zimbabwe
17 million women of
screening age
TruScreen continues to work
with the Ministry of Health
and the National Aids
Council to expand on our
work in Masvingo province,
where 14,000 women
have been screened to date.
Central Africa
114 million women
of screening age
Re–validation of TruScreen
for government programs
is to be completed
following which new
tenders will be submitted
for continuation of this
program.
TruScreen has been in
discussions with major
African distributor Phillips
Pharma to validate TruScreen
for use in Kenya, Nigeria,
Uganda, Ghana and
Tanzania
TruScreen has been
approached by the Baylor
Foundation in Eswatini
(Swaziland) re screening
there.

37
Saudi Arabia
11 million women of
screening age
Commercial rollout
commenced in FY24, with
Private Health
Insurancereimbursement
for TruScreenavailable
from most Private
Health Insurers, and as
in Uzbekistan, TruScreen is
under consideration as a
solution for a national
screening program for the
7 million women under
public healthcare in Saudi
Arabia
A 500 patient trial found
that TruScreen was 25%
more sensitive (83.3% v
66.7%) than Pap in
detecting cervical cancer
and pre-cancers, and that
it was a practical and
reliable tool for use in
various health settings.
The investigators
concluded that:
“the trial provides an evidence
based approach for policymakers
when selecting the optimal cervical
cancer screening strategy in
countries without an established
national screening program”

38
South and
South East Asia

39
Indonesia
96 million women of
screening age
TruScreen distributor PT
Mursmedic has commenced
product registration in
Indonesia to enable
validation trials in the worlds
largest Islamic Country,
where 36,000 women die
annually from Cervical
Cancer
South & SE Asia
(and South Africa)
142 million women of
screening age
Indonesia has no national
screening program but a
growing business and
middle class seeking
access to modern health
technologies
We have authorised
distributors to market
TruScreen in South Africa
and Sri Lanka, and in the
second half of FY25 will focus
on India, Bangladesh and
the ASEAN countries
(Thailand, Singapore,
Malaysia and Philippines)
where we have been
negotiating for distribution.
Source: https://www.hollows.org/au/latest/australia-visit-building-strong-women-health-leaders-in-southeast-asia

40
Technology
Improvements
And Cost Reductions

Working with key suppliers in
China and USA to improve the
performance of sputtering - the
key manufacturing process for
our Single Use Sensor
production. These
improvements will improve the
sensitivity and specificity of our
technology and also have a
significant effect on Single Use
Sensor costs.
41
Technology Improvements
Identifying and validating
improved optical and
electrical components,
increasing the efficiency of
our sub-assembly
manufacture, improving
device performance and
lowering device production
costs
TruScreen has implemented or is actively engaged in the
following device and Single Use Sensor improvement programs

Technology
improvements
42
Building upon the previous Self Calibration
Software Development, to enable an
increase of the in-field service interval of the
device from 18 months to 3 years or more
Target 96% of devices self-calibrating
for a minimum of 3 years

43
Operating cost improvements
TruScreen has implemented or is actively engaged in the following head office cost improvements:
Reduced head office
contractor day/hour
commitments
Reduced head
office employee
numbers
Conducted and continuing
to conduct a review of all
suppliers (e.g IT, Telco,
Premises et al) to deliver
savings through FY 2025
and 2026

Key
Takeaways
44

45
Key takeaways
TruScreen targeting cash
flow break even by end of
March 2025
TruScreen China sales
growth outperforming
growth rates of
competing technologies
(e.g. HPV DNA)
Technology improvements
to increase device
performance and head office
costs to be controlled
Expand on government
administrative changes
to realise sales growth
in Vietnam and Mexico
Target Govt and NGO
funded programs in
countries such as Zimbabwe
and Uzbeksistan
Market expansion to
continue with China the
key focus

Thank you
Q&A
46

47
A World Without
Cervical Cancer
www.truscreen.com

Contact Us For More Information
48
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
Suite 3, Level 3, 18-20 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
Guy Robertson
Chief Financial
Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
TruScreen
Suite 3, Level 3, 18-20 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
@TruscreenGroupLtd@TruscreenGroupLimited

49
•This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 27 March 2024. This presentation contains summary
information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a
general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a
possible investment in the Company. This presentation should be read in conjunction with the Company’s annual report, market releases and other
periodic and continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement
or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.
Not financial product advice
•This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities,
and has been prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment
decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and
needs and consult a financial adviser, solicitor, accountant or other professional adviser if necessary.
Past performance
•Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an
indication of future performance. No representations or warranties are made as to the accuracy or completeness of such information.
Future performance
•This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-
looking information is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which
are outside of the Company’s control, and may involve significant elements of subjective judgement and assumptions as to future events which may or
may not be correct. A number of important factors could cause actual results or performance to differ materially from any forward-looking statements.
No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking
statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including
the Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information,
future events or results or otherwise.
Disclaimers

50
References
1.WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news-
room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2.WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020
3.Human papillomavirus and cancer (who.int)
4.Wei, Y., Wang, W., Cheng, M., Hong, Z., Gu, L., Niu, J., Di, W., & Qiu, L. (2021). Clinical evaluation of
a real-time optoelectronic device in cervical cancer screening.European journal of obstetrics,
gynecology, and reproductive biology,266, 182–186.
https://doi.org/10.1016/j.ejogrb.2021.09.027.
5.Vet, J. N., Haindl, J. P., Velasquez, C., Parker, L. J., Burns, M. I., Morrell, S., & Campion, M. J.. (2022).
A Performance Evaluation of an Optoelectronic Cervical Screening Device in Comparison to
Cytology and HPV DNA Testing.European Journal of Gynaecological Oncology,43(2), 213.
https://doi.org/10.31083/j.ejgo4302027
6.Central Intelligence Agency, The World Fact Book, CHINA, People and Society, Female ages 25-64
Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/ch.html
7.Central Intelligence Agency, The World Fact Book, VIETNAM, People and Society, Female ages 25-
64 Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/vm.html
A World Without
Cervical Cancer

About
TruScreen
Technology
51

52
TruScreen transformation of cervical cancer screening
Perform TestObtain Result
Moving from multi-step, expensive screening to Point-of-Care Solution
Specimen
Collection
Label, Packaging
And Transport
2 - 3 weeks
Current cervical screening process is multi-step, error prone, people dependant,
uncomfortable for a woman, slow, expensive and inefficient (loss in follow up)
Advantages
⚫Integration into healthcare systems:
hospitals, clinics
⚫Immediate management of positive
results with streamlined patient flow
efficiency
10
minutes
⚫Better patient experience
⚫Cost saving, time saving
⚫More efficient utilization of healthcare
resources
Slide
Preparation
FixationStaining
Microscopic
Examination
InterpretationReporting
Communication
Of Results

53
Trusted Clinical Performance
High sensitivity in
detecting CIN2+*
High specificity in
detecting CIN2+*
Extensive body of
clinical evidence
TruScreen
®
has been
found to be as sensitive
in detecting CIN2+ as
cytology**
4
TruScreen
®
has been
found to be more
specific in detecting
CIN2+ as cytology**
4
Over 40,000
women in clinical
trials to date***
* CIN2: A cervical biopsy finding that means moderately abnormal cells were found on the surface of the cervix.
CIN2 is usually caused by infection with certain types of human papillomavirus (HPV). Source: NIH, www.cancer.gov
** Data from large observational study, Cytology used was ThinPrep
*** Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II

54
Why choose TruScreen
®
?
* HPV DNA, Human Papilloma Virus DNA test
Liquid Based
Cytology (LBC)
HPV DNA*
Real time results
✓
Low infrastructure costs
✓
Strong clinical results
✓✓✓
Objective results
✓
Low training threshold
✓
Portable
✓
No cell or tissue samples taken
✓